Gene · 94
Papers4,014
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 4,014
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dysregulated circulating miR-4429 serves as a novel non-invasive biomarker and is correlated with EGFR mutation in patients with non-small cell lung cancer. | Bosn J Basic Med Sci | 2022 | 35167433 | PubTator, text mining | PubMed |
| Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia. | Thorax | 2022 | 35165143 | PubTator, text mining | PubMed |
| Organ-Specific Endothelial Cell Differentiation and Impact of Microenvironmental Cues on Endothelial Heterogeneity. | Int J Mol Sci | 2022 | 35163400 | PubTator, text mining | PubMed |
| Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases. | Int J Mol Sci | 2022 | 35163328 | PubTator, text mining | PubMed |
| Soluble Endoglin Stimulates Inflammatory and Angiogenic Responses in Microglia That Are Associated with Endothelial Dysfunction. | Int J Mol Sci | 2022 | 35163148 | PubTator, text mining | PubMed |
| 1,3-diarylpyrazolones as potential anticancer agents for non-small cell lung cancer: Synthesis and antiproliferative activity evaluation. | Chem Biol Drug Des | 2022 | 35156777 | PubTator, text mining | PubMed |
| Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement✰. | Am J Prev Cardiol | 2022 | 35146468 | PubTator, text mining | PubMed |
| Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions. | Microvasc Res | 2022 | 35143811 | PubTator, text mining | PubMed |
| Role of Canonical Wnt/β-Catenin Pathway in Regulating Chondrocytic Hypertrophy in Mesenchymal Stem Cell-Based Cartilage Tissue Engineering. | Front Cell Dev Biol | 2022 | 35141220 | PubTator, text mining | PubMed |
| Emerging roles of inflammation-mediated endothelial-mesenchymal transition in health and disease. | Inflamm Regen | 2022 | 35130955 | PubTator, text mining | PubMed |
| Capillary Malformation-arteriovenous Malformation Type 2: A Case Report and Review. | Acta Derm Venereol | 2022 | 35088870 | PubTator, text mining | PubMed |
| Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation. | Blood Adv | 2022 | 35078207 | PubTator, text mining | PubMed |
| Pulmonary arteriovenous malformation revealing Osler-Weber-Rendu disease: A case report. | Clin Case Rep | 2022 | 35070308 | PubTator, text mining | PubMed |
| Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival. | Chest | 2022 | 35063447 | PubTator, text mining | PubMed |
| LRG1: an emerging player in disease pathogenesis. | J Biomed Sci | 2022 | 35062948 | PubTator, text mining | PubMed |
| Acquired pulmonary arteriovenous malformation associated with bronchiectasis: a case report. | J Med Case Rep | 2022 | 35057821 | PubTator, text mining | PubMed |
| Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension. | Biomedicines | 2022 | 35052850 | PubTator, text mining | PubMed |
| The Role and Research Progress of Inhibitor of Differentiation 1 in Atherosclerosis. | DNA Cell Biol | 2022 | 35049366 | PubTator, text mining | PubMed |
| Impact of Arterial Hypertension on the Eye: A Review of the Pathogenesis, Diagnostic Methods, and Treatment of Hypertensive Retinopathy. | Med Sci Monit | 2022 | 35046380 | PubTator, text mining | PubMed |
| The versatility and paradox of BMP signaling in endothelial cell behaviors and blood vessel function. | Cell Mol Life Sci | 2022 | 35044529 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/94/papers?page=45